Advanced Filters
noise

Burien, Washington Clinical Trials

A listing of Burien, Washington clinical trials actively recruiting patient volunteers.

Found 324 clinical trials
A Allison Everett

Paclitaxel Coated Balloon for the Treatment of Chronic bEnigN sTricture- Esophagus

To evaluate the safety and efficacy of the ProTractX3™ DCB for the treatment of benign esophageal strictures.

22 years of age All Phase 3
J Jeffrey S McLean, PhD

Variation in Gingival Inflammatory Responses

The aim of this NIH National Institute of Dental and Craniofacial Research (NIDCR) funded study is to identify molecular mechanisms underlying observed variations in human responses to natural accumulation and maturation of dental plaque.

18 - 35 years of age All Phase N/A
D Diana Sullivan

Proximal Internal Carotid Artery Acute Stroke Secondary to Tandem or Local Occlusion Thrombectomy Trial

The primary objective is to establish the efficacy of intra-arterial (IA) mechanical thrombectomy (MT) with extracranial proximal carotid artery acute stenting versus non-stenting approaches in patients with acute ischemic stroke (AIS) from intracranial vessel occlusion (IVO) in the anterior circulation and have a proximal carotid occlusive disease (occlusion or severe …

18 - 79 years of age All Phase 3
J Julie Graff, MD

Carboplatin or Olaparib for BRcA Deficient Prostate Cancer

This is an unblinded, randomized clinical study comparing the efficacy of DNA damaging chemotherapy using carboplatin, to standard of care therapy for patients who have metastatic castrate resistant prostate cancer. This trial will use olaparib or carboplatin as initial therapy with crossover to the alternate or second-line drug after first …

18 years of age Male Phase 2
N Nathan Hansen

Personalized Cancer Stem Cell High-Throughput Drug Screening for Glioblastoma

Proposed treatment of subjects with newly diagnosed glioblastoma with novel personalized drug regimens identified to be effective in vitro using cancer stem cells derived from their individual tumors, alongside standard of care radiation and TMZ.

18 years of age All Phase N/A
B Branda Levchak

Ultrasound to Facilitate Stone Passage

This is a prospective, open-label, multi-center study to test the clinical feasibility of facilitating stone passage by the combination of breaking and repositioning stones with ultrasound, without the need for anesthesia.

18 years of age All Phase N/A
S Site Public Contact

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

This phase II Expanded Lung-MAP treatment trial tests tepotinib with or without ramucirumab for the treatment of patients with advanced non-small cell lung cancer that has spread from where it first started (primary site) to other places in the body (stage IV) or that has come back after a period …

years of age All Phase 2
A Anastasia Whitson, BS

Optimizing Infection Prophylaxis Prior to Shoulder Surgery

The goal of this interventional study is to determine the amount of skin C. acnes reduction with increased pressure during the chlorhexidine gluconate, brand name ChloraPrep, application. The main question it aims to answer is: Does changing the pressure applied during the ChloraPrep application impact the amount of C. acnes …

18 - 89 years of age Male Phase N/A
J Janet Garza, RN

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, and preliminary clinical activity of Tulmimetostat as a monotherapy in patients with advanced solid tumors and lymphomas.

18 years of age All Phase 1/2
R Rita Mehta, MD

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence …

18 - 60 years of age Female Phase 3

Simplify language using AI